In a law review article entitled “The Death of the Genus Claim,” 1 which published in the aftermath of the Federal Circuit decision in Idenix v. Gilead, 941 F.3d 1149 (Fed. Cir. 2019), the authors stated that, “in the past thirty years, there are virtually no significant examples of genus claims in the life science fields upheld on appeal as compliant with § 112(a) outside the unique context of . . . ‘interference” proceedings.’” The authors accused the Federal Circuit of “abandon[ing] a practical focus on whether others could make use of the claimed invention in favor of a fruitless search for the exact boundaries of that invention” and characterized the court’s “‘full scope possession’ theory [as] invalidat[ing] a genus claim unless the patent can show exactly which species within the genus will work as intended.”